Articles:

This new API (active pharmaceutical ingredient) manufacturing plant is a flagship facility for Pfizer’s regional network, a $1bn SGD investment covering almost 430,000 square feet and delivered entirely during the COVID-19 pandemic.

A small amount of this could be diverted to the much more commercially valuable (margin-wise) supply of high purity solvents..Waste recycling within plants is something many manufacturers are looking to increase.

This does not come without quality and technical challenges.Local recycling, which is directly discouraged by some regulations, can increase batch-to-batch cross contamination.Recycling can concentrate impurities, an issue that requires monitoring and can drive the need for further processing.

The technical issues are primarily around ensuring solvent waste is neither mixed with other solvents nor with other water-based waste streams.In fact, the segregation of waste streams in manufacturing is a very significant first step as this opens the possibility of multiple approaches to extraction, recycling and treatment..

Although there wasn’t a focus on recycling outside of the factory, there seemed to be many more potential solutions in this area.

With the right segregation, there are opportunities for waste management companies to work with manufacturers to find both technically and economically sound solutions to recycle back into manufacturing and/or into other supply chains.We’ll find that small steps make a significant difference.

It won’t take long..The Supply Chain and SMEs.

At Bryden Wood we’re starting to see a real surge of interest from lower tiers of the supply chain, which supports the idea that one major benefit of all of this will be that we'll unlock SMEs in a way that probably hasn't been done before.In other words, the disintermediation will start to bear significant fruit.